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tions, but no tools are yet available. We tested the ability of an IBD monitoring tool, which can
be used with mobile technologies, to assess disease activity in patients with Crohn’s disease
(CD) or ulcerative colitis (UC).METHODS: We performed a prospective observational study to develop and validate a mobile health index
for CD and UC, which monitors IBD disease activity using patient-reported outcomes. We
collected data from disease-specific questionnaires completed by 110 patients with CD and 109
with UC who visited the University of California, Los Angeles, Center for IBD from May 2013
through January 2014. Patient-reported outcomes were compared with clinical disease activity
index scores to identify factors associated with disease activity. Index scores were validated in
301 patients with CD and 265 with UC who visited 3 tertiary IBD referral centers (in California
or Europe) from April 2014 through March 2015.RESULTS: We assessed activity of CD based on liquid stool frequency, abdominal pain, patient well-being,
and patient-assessed disease control, and activity of UC based on stool frequency, abdominal
pain, rectal bleeding, and patient-assessed disease control. The indices identified clinical dis-
ease activity with area under the receiver operating characteristic curve values of 0.90 in pa-
tients with CD and 0.91 in patients with UC. They identified endoscopic activity with area under
the receiver operating characteristic values of 0.63 in patients with CD and 0.82 in patients with
UC. Both scoring systems responded to changes in disease activity (P < .003). The intraclass
correlation coefficient for test-retest reliability was 0.94 for CD and for UC.CONCLUSIONS: We developed and validated a scoring system to monitor disease activity in patients with CD
and UC that can be used with mobile technologies. The indices identified clinical disease activity
with area under the receiver operating characteristic curve values of 0.9 or higher in patients
with CD or UC, and endoscopic activity in patients with UC but not CD.Keywords: Patient-Reported Outcomes; Telemedicine; Severity; Management.r: AUC, area under the curve; CD, Crohn’s
e activity index; DA-VAS, disease activity
rvey Bradshaw index; Hgb, hemoglobin;
ase; LUMC, Leiden University Medical
; mHI, mobile health index; NPV, negative
al Mayo score; PPV, positive predictive
outcomes; ROC, receiver operating char-
ical colitis activity index; SES-CD, simple
s disease; UC, ulcerative colitis; UCI,
University of California, Irvine; UCLA, University of California, Los Angeles;
VAS, visual analogue scale.
Most current article
© 2016 by the AGA Institute
1542-3565/$36.00
http://dx.doi.org/10.1016/j.cgh.2015.10.035
December 2016 mHealth Index for IBD Monitoring 1743See editorial on page 1751; see similar article on
page 1697.
he shift from symptom-oriented to prevention-Toriented care delivery has accelerated the devel-
opment of mobile health (mHealth) technologies and is
thought to radically transform health care delivery.1
Smartphone adoption is increasing rapidly, with 64%
of Americans using smartphones in 2014 of which 62%
used their telephones to look up health information.2
Many health apps are available, most of which provide
health information or support data collection.3 For pa-
tients with inflammatory bowel diseases (IBD), apps
are available that assist in tracking symptoms, logging
meals, and managing medications.4,5 These apps can
create reports for providers but do not allow for real-
time interactions between patient and provider.
Self-monitoring and self-management for chronic dis-
eases is widely practiced in diabetes care6 and anti-
coagulation therapy.7 Additionally, e-technologies for
symptom reporting between patients and providers are
increasingly used in chronic diseases.8 Several systems
for online symptom reporting and disease management
have been developed for IBD. In the Danish Constant-Care
web system, patients with ulcerative colitis (UC) filled out
a clinical symptom score and logged fecal calprotectin
levels weekly; based on these scores the system made
real-time recommendations for adjusting mesalamine
dosing. This approach was shown to empower patients
and decrease relapse duration.9,10 Similarly, individuali-
zation of infliximab dosing in patients with Crohn’s dis-
ease (CD) was reported to be practical and feasible.11 A
study evaluating another home tele-management system
in UC (UC-HAT) did not show significant differences in
disease activity and quality of life between users and
control subjects, and more than one-third of the patients
discontinued participation.12 An ongoing multicenter
randomized controlled trial is testing the use of a mobile
tele-management system using text messaging in IBD.
This system sends personalized alerts and educational
texts, and assesses symptoms and side effects, based on
which treatment can be modified.13
Patient-reported outcomes (PROs) are increasingly
used to evaluate health status, and the importance of
PROs in outcome measurement, symptom management,
and quality improvement efforts is increasingly recog-
nized.14 Furthermore, the use of PROs as primary
outcome measures for evaluating effectiveness of IBD
interventions is progressively supported by the Food and
Drug Administration.15 Therefore, PROs are promising
for use in mHealth apps. An example is the Health-
PROMISE app, which tracks patient-reported quality of
life scores in patients with IBD and provides decision
support to physicians.16 However, accurate e-monitoring
tools for disease activity in IBD are yet to be developed.
Previous efforts have aimed to develop PRO question-
naires by adjusting existing scores.17–19 We aimed toidentify the most optimal PRO score to use on an IBD
disease-monitoring app. The best PROs were selected
from an exhaustive list of PROs in a prospective cohort of
patients with IBD. Subsequently, the developed scores
were tested prospectively in an independent cohort at 3
independent IBD centers.Methods
Design
We performed a prospective, observational study that
aimed to develop and validate an mHealth index (mHI)
for CD and UC that accurately monitors IBD disease
activity using PROs. The study consisted of 2 phases: a
development phase and a validation phase. During the
development phase the mHIs were developed using
collected PROs and clinical disease activity indices.
During the validation phase the developed mHIs were
validated in an independent cohort.Population
Development phase. Patients with IBD were identified
during clinic visits between May 2013 and January 2014
at the University of California, Los Angeles (UCLA) Center
for IBD. Patients with esophageal or anal CD involvement
alone, patients with a pouch or stoma, and pregnant
women were excluded. Eligible patients filled out
disease-specific questionnaires assessing PROs of most
common clinical disease activity indices: partial Mayo
(pMayo), simple clinical colitis activity index (SCCAI),
and modified Truelove and Witts index for UC; Harvey
Bradshaw index (HBI) and CD activity index (CDAI)
including a 7-day diary before the visit (Supplementary
Figure 1) for CD. Additionally, patients were asked to
assess their symptoms and perceived disease activity
using visual analogue scales (VAS). The PROs were
categorized into 10 domains: stool frequency, abdominal
pain, general well-being, urgency, stool consistency,
rectal bleeding, fever, anorexia, nausea/vomiting, and
perceived disease activity (Table 1).
During clinic visits, vital signs were measured and
physicians collected the physician-reported outcomes
required for the clinical disease activity indices (Table 1).
Hemoglobin (Hgb), hematocrit, white blood cell count,
platelets, albumin, C-reactive protein, and erythrocyte
sedimentation rate were requested. Furthermore, stool
testing for calprotectin was requested either at the pa-
tient’s preferred laboratory or using a free stool kit
(Genova Diagnostics, Asheville, NC) picked up at the
patient’s home. A dedicated study nurse (E.K.) followed
up with patients via telephone or e-mail to ensure lab-
oratory and stool tests were performed.
Validation phase. Eligible patients with IBD were
identified during clinic and endoscopy visits between
Table 1. Collected PROs and Clinical Markers in CD and Patients With UC
Domain Question CD UC
1. Stool frequency Number of liquid/very soft stools for each of the last 7 days X
How many stools did you have yesterday during the day? X X
How many stools did you have yesterday during the night? X X
How many stools do you have normally during the day? X X
How many stools do you have normally during the night? X X
2. Abdominal pain Abdominal pain for each of the last 7 days (no/mild/moderate/severe) X
Abdominal pain (no/mild/moderate/severe) X
Abdominal pain (no abdominal pain/with bowel actions/continuous) X X
Rate your abdominal pain on a scale from 0 to 10 (VAS) X X
3. General well-being General well-being for each of the last 7 days (very well/slightly below par/poor/
very poor/terrible)
X
General well-being (very well/slightly below par/poor/very poor/terrible) X
General well-being (perfect/very good/good/average/poor/terrible) X
Well-being (no impairment/impaired, but able to continue activities/activities reduced/unable
to work)
X X
Rate your well-being on a scale from 0 to 10 (VAS) X X
4. Urgency Urgency of defecation (no urgency/hurry/immediate/incontinence) X X
5. Stool consistency Stool consistency (normal or variably normal/semiformed/liquid) X X
Do you take opiates or lomotil/imodium for diarrhea? X X
How often do you take antidiarrheals? (0–10 VAS) X X
6. Rectal bleeding What % of bowel movements contains visible blood? (none/less than 50%/50% or more/
blood alone)
X X
Amount of blood in stool (none/trace/occasionally frank [bright red]/usually frank) X X
How often do you experience rectal bleeding? (0–10 VAS) X X
7. Fever Fever on each of the last 7 days X
8. Anorexia Loss of appetite (yes/no) X X
9. Nausea/vomiting Nausea and/or vomiting (yes/no) X X
10. Disease activity How well do you feel your disease is under control? (0–10 VAS) X X
11. Clinical markers Temperature X X




Extraintestinal manifestations X X
Physician global assessment of disease activity X X
Hgb, hematocrit, white blood cell, platelets, albumin, C-reactive protein, erythrocyte
sedimentation rate (blood) and calprotectin (stool)
X X
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centers (UCLA; University of California, Irvine [UCI]; and
Leiden University Medical Center [LUMC], the
Netherlands). Patients who participated in the devel-
opment phase of the study were excluded. For patients
with CD, the developed mHI-CD and HBI were
completed during clinic visits; during endoscopic visits,
the simple endoscopic score for CD (SES-CD) was addi-
tionally completed. For patients with UC, the mHI-UC
and pMayo were collected during clinic visits, and the
Mayo endoscopic subscore was additionally obtained
during endoscopic visits. Patients at LUMC completed a
Dutch version of the mHI-CD and mHI-UC. After trans-
lation to Dutch, the questionnaires were translated back
to English by an independent translator; the Dutch
questionnaire was then revised and retested. To assess
sensitivity of the mHI to detect changes in clinical dis-
ease activity, a subset of patients was included a second
time during scheduled follow-up visits. To assess test-
test reliability, a subset of UCLA patients was asked tocomplete a second questionnaire at home after their
clinic visit.Definitions
For CD, clinical disease activity was defined as an HBI
>4 or a CDAI >150. A change of 3 in HBI was
considered a clinically relevant change.20 Endoscopic
disease activity was defined as an SES-CD >3. For UC,
clinical disease activity was defined as a pMayo >2, a
MTWI >3, or an SCCAI >2. A change of 3 in the pMayo
was considered a clinically relevant change.18 Endo-
scopic disease activity was defined as a Mayo endoscopic
subscore >1.Ethical Considerations
All patients consented to participate in this study.
This study was approved by the institutional review
December 2016 mHealth Index for IBD Monitoring 1745boards of participating centers under the following
protocol numbers: UCLA, IRB#13-000402; UCI, HS#
2014-1231; and LUMC, P14.158.
Statistical Analysis
Descriptive statistics were used for clinical charac-
teristics and demographic information. Numeric values
are presented as mean and standard deviation or median
and range. SAS version 9.2 (SAS Institute, Cary, NC) was
used for statistical analyses.
Development phase. Univariate logistic regression
was performed using disease activity (HBI >4 for CD or
pMayo >2 for UC) as the dependent variable and the
PROs as independent variables. For each of the PROs,
different cutoffs were used, which roughly created linear
associations between the groups and the chance of active
disease. Because different PROs represented the same
domain (Table 1), the variables with the highest Wald
chi-square value for predicting clinical disease activity
were selected within each domain for inclusion in the
multivariate logistic regression models. If 2 variables
within the same domain had a similar predictive value
(difference between Wald chi-square values <0.5), both
were tried in separate models unless the question type
was less preferable. Because of usability on a mobile
application VAS, yes/no, or numeric questions were
preferred over categorical questions; within those,
questions with less response options were preferred.
Variables with a P value >.1 in the univariate analysis
were omitted from subsequent analyses. Stepwise for-
ward multivariate logistic regression was performed
with clinical disease activity as the dependent variable
and the selected PROs as independent variables. A sig-
nificance level of P < .1 was required for entry in the
model and a significance level of P < .1 to stay in the
model. Several models were performed using different
clinical disease activity indices to define clinical disease
activity as the dependent variable.
Composite scores were created using the regression
coefficients of independent predictors in the multivariate
model. Spearman correlation coefficients were estimated
between the newly developed mHIs and clinical disease
activity indices. Receiver operating characteristic (ROC)
curves were used to assess the capability of the mHI to
discriminate active versus nonactive disease using
different clinical disease activity indices, and the areas
under the curves (AUC) were calculated. The composite
score with overall highest AUC using different gold
standards was selected.
Because the main aim of the developed score was to
identify patients at risk for active disease, we defined the
optimal cutoff for disease activity as a negative predic-
tive value (NPV) of 95% and a sensitivity of 85%
while maintaining maximum specificity. The overall
prevalence of active disease was estimated at 22% based
on cross-sectional cohort data from UCLA.Validation phase. To validate the mHI against clinical
and endoscopic disease activity indices, the mHI-UC was
compared with the pMayo and the endoscopic subscore
of the Mayo; the mHI-CD was compared with the HBI and
SES-CD. Spearman correlation coefficients between the
scores were calculated and ROC curves to assess the
ability to predict clinical and endoscopic disease activity
were generated. To assess sensitivity to change, we
compared patients who clinically improved, remained
stable, and deteriorated. A Kruskal-Wallis test was used
to compare groups. Test-retest reliability was assessed
by the intraclass correlation coefficient. The performance
of the VAS for patient-reported disease activity (DA-VAS)
as single predictor for clinical and endoscopic disease
activity also was assessed.Results
Development Phase
In total, 219 patients (110 CD and 109 UC) were
included in the development phase of the study
(Figure 1A, Table 2). In 108 out of 110 patients with CD
the HBI was calculated, whereas the CDAI could only be
calculated in 93 out of 110. The pMayo, SCCAI, and
modified Truelove and Witts index were calculated in all
patients with UC. Complete laboratory and stool tests
were obtained from only 48% of patients. Despite
intensive follow-up by a dedicated research nurse (E.K.),
39% of patients did not perform stool testing and 13%
did not have laboratory values drawn. Additionally, 14%
of patients had blood drawn, but laboratory sets were
incomplete because of protocol deviations.
Univariate logistic regression was performed for
PROs and blood and stool tests (Supplementary Tables 1
and 2). Stool frequency, abdominal pain, general well-
being, urgency, and patient-reported disease activity
were all strong predictors for clinical disease activity in
both CD and UC (P < .0001). Incontinence was only
present in 3% of patients and did not predict disease
activity in either CD (P ¼ .54) or UC (P ¼ .99). In CD the
use of antidiarrheals was predictive for disease activity
(P ¼ .019) but not in UC (P ¼ .96), whereas the VAS
assessing frequency of antidiarrheal use was a predictor
for neither CD (P ¼ 1.00) nor UC (P ¼ .26). Rectal
bleeding was a predictor for disease activity in both UC
(P < .0001) and CD (P ¼ .019). Anorexia was predictive
in both CD (P ¼ .019) and UC (P ¼ .0025), whereas
nausea and vomiting predicted only CD disease activity
(P ¼ .035) and not UC disease activity (P ¼ .14). High C-
reactive protein (P ¼ .0009), high erythrocyte sedimen-
tation rate (P ¼ .0022), low Hgb (P ¼ .022), and low
albumin (0.034) were predictors for clinical disease ac-
tivity in CD. High calprotectin was not a significant pre-
dictor for CD disease activity (P ¼ .054), although
calprotectin as continuous variable had predictive value
Figure 1. Inclusion flow-
charts for development
phase (A) and validation
phase (B).
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.28), and high white blood cell (P ¼ .11) were not pre-
dictive in CD (Supplementary Table 1). In UC high
C-reactive protein (P ¼ .0067), high calprotectin (P ¼
.022), high white blood cell (0.013), high erythrocyte
sedimentation rate (P ¼ .028), and low hematocrit (P ¼
.0047) were all predictive for clinical disease activity.
Low albumin (P ¼ .98) was not predictive for clinical
activity in UC, although albumin as continuous variable
was (P ¼ .02). Low platelets (P ¼ .99) and low Hgb (P ¼
.13) were not predictive for disease activity in UC,
whereas Hgb as continuous variable (P ¼ .032) was
(Supplementary Table 2).The most representative PROs were selected for in-
clusion in the multivariate regression model
(Supplementary Tables 1 and 2). Because of low
completion rates of laboratory testing despite intensive
follow-up, laboratory tests were initially excluded from
the multivariate analysis and score development. In CD, 4
composite scores were developed (Supplementary
Table 3); in UC, 11 composite scores were evaluated
(Supplementary Table 4). Addition of laboratory vari-
ables to the selected models decreased the sample size
and therefore the power of the regression models;
addition of the laboratory variables to the model did not
result in inclusion of these variables in the models,
Table 2. Demographics of Included Patients in Development and Validation Phase of the Study
Development phase Validation phase
CD UC CD UC
N 110 109 301 265
Median age, median (range) 33 (19–79) 35 (18–81) 33 (18–75) 42 (18–86)
Male, n (%) 56 (51) 57 (52) 144 (48) 132 (50)a
Smoking, n (%) 9 (8) 7 (6)a 19 (6)b 12 (5)c
Age at diagnosis, median (range) 24 (8–68) 28 (10–81) 25 (8–66) 29 (2–76)
Disease duration, median (range) 8 (0–46) 6 (0–52) 8 (0–52) 7 (0–59)
Surgical history, n (%) 48 (44) 1 (1) 132 (44)d 13 (5)d
CD fistulizing disease, n (%) 5 (5)a — 59 (20)a —
Active disease (HBI >4 /pMayo >2), n (%) 32 (30)a 37 (34) 82 (27) 82 (31)
an ¼ 1 unknown.
bn ¼ 8 unknown.
cn ¼ 9 unknown.
dn ¼ 2 unknown.
December 2016 mHealth Index for IBD Monitoring 1747because they did not reach the required significance level
of P < .1 for entry in the model.
For CD the selected composite score (Table 3) had an
AUC of >0.95 for predicting clinical disease activity,
using both CDAI and HBI as gold standards (0.951 and
0.963, respectively). The Spearman correlation co-
efficients were 0.837 and 0.830, respectively
(Supplementary Table 3). The optimal cutoff for the
mHI-CD to predict clinical disease activity was set at
5.5, resulting in an NPV of 96%, positive predictive
value (PPV) of 63%, sensitivity of 88%, and specificity
of 85%. For UC the selected composite score (Table 3)
had an AUC of >0.91 to predict disease activity using
pMayo, SCCAI, and modified Truelove and Witts index
as gold standards (0.960, 0.915, and 0.913, respec-
tively). The Spearman correlation coefficients were
0.820, 0.832, and 0.790, respectively (Supplementary
Table 4). The optimal cutoff for the mHI-UC to predict
clinical disease activity was set at 4.99, resulting in an
NPV of 97%, PPV of 72%, sensitivity of 89%, and
specificity of 90%.Table 3. Calculation of the mHI-CD and mHI-UC
mHI-CD questions Answer Score
Number of liquid/very soft stools/day 0 0.0000 How m
have1–2 1.6983
3 3.3966
Abdominal pain No 0.0000 Rate yo
scaleYes 2.3868
Rate your well-being on a scale from
0 to 10 (0 ¼ worst, 10 ¼ best)
8–10 0.0000 How of
(0 ¼4–7 2.1336
0–3 4.2672
How well do you feel your disease is
under control (0 ¼ no disease activity,
10 ¼ worst disease activity)
0–2 0.0000 How w
(0 ¼3–6 2.1175
7–10 4.2350
Total score (SUM) Total sValidation Phase
A total of 301 patients with CD (UCLA, n ¼ 127; UCI,
n ¼ 82; LUMC, n ¼ 92) and 265 patients with UC (UCLA,
n ¼ 119; UCI, n ¼ 67; LUMC, n ¼ 79) were analyzed in
the validation phase (Figure 1B, Table 2). For CD the
Spearman correlation coefficient was 0.75 (P < .0001)
between HBI and mHI-CD, the AUC of the ROC for pre-
dicting clinical disease activity was 0.90, and a sensitivity
of 94% and specificity of 67% were achieved using a
cutoff of 5.5 (Figures 2A and 2B). To achieve the
optimal NPV of 95% and sensitivity of 85%, the cutoff in
this cohort would be 6.38, which would result in 85%
sensitivity, 80% specificity, 95% NPV, and 55% PPV. The
mHI-CD was poorly correlated with the SES-CD (r ¼ .30;
P ¼ .0039), with an AUC of 0.63 (Figures 2A and 2C).
For UC the Spearman correlation coefficient was 0.72
(P < .0001) between pMayo and mHI-UC, the AUC of the
ROC for predicting clinical disease activity was 0.91, and
a sensitivity of 73% and specificity of 90% specificity
were achieved using a cutoff of 4.99 (Figures 2D andmHI-UC questions Answer Score





ur abdominal pain on a




ten do you experience rectal bleeding?
none, 10 ¼ always)
0–3 0.0000
4–10 2.2019
ell do you feel your disease is under control





Figure 2. Performance of the developed mHI scores to detect disease activity in CD (A–C) and UC (D–F). ROC curves of the
mHI to predict clinical and endoscopic disease activity (A and D), scatter plot of the mHI versus clinical disease activity scores
(B and E), and endoscopic disease activity scores (C and F).
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which would result in 85% sensitivity, 80% specificity,
95% NPV, and 55% PPV. The mHI-UC was strongly
correlated with the Mayo endoscopic subscore (r ¼ .60;
P < .0001), with an AUC of 0.82 (Figures 2D and 2F).
Sensitivity to change was assessed in a subset of 50
patients with CD and 44 patients with UC. Median time
between questionnaires was 46 days (range, 2–352) for
CD and 57.5 days (range, 3–275) for UC. Four (8%) pa-
tients with CD deteriorated, 31 (62%) had stable disease
activity, and 15 (30%) improved. Of the patients with UC,
5 (11%) deteriorated, 27 (61%) remained stable, and 12
(27%) improved. There was a significant difference in
mHI between patients who clinically improved, remained
stable, or worsened, with either CD (P ¼ .0030) or UC
(P ¼ .0025) (Figures 3A and 3C). Test-retest reliability
was assessed in a subset of 40 patients with CD and 37
patients with UC. The median time to second question-
naire completion was 21 hours (range, 7–36) for the mHI-
CD and 23 hours (range, 11–144) for the mHI-UC. The
intraclass correlation coefficient was 0.94 (confidence
limits, 0.89–0.97) for the mHI-CD and 0.94 (confidence
limits, 0.89–0.97) for the mHI-UC (Figures 3B and 3D).
One question in both the mHI-CD and the mHI-UC
assessed patient-reported disease activity using a VAS
(DA-VAS). In patients with CD (n ¼ 301) the DA-VAS hada Spearman correlation of 0.63 (P < .0001) with the HBI,
and the AUC for predicting clinical disease activity was
0.83 (compared with r ¼ .75 and AUC ¼ 0.90 for the full
mHI-CD). The CD DA-VAS was weakly correlated with the
SES-CD (r ¼ .21; P ¼ .040), and had an AUC to predict
endoscopic disease activity of 0.59 (compared with r ¼
0.30 and AUC ¼ 0.63 for the full mHI-CD). The DA-VAS
was not significantly different among patients who
deteriorated, remained stable, or improved (P ¼ .12). In
patients with UC (n ¼ 265) the DA-VAS had a Spearman
correlation of 0.67 (P < .0001) with the pMayo, and the
AUC for predicting clinical disease activity was 0.86
(compared with r ¼ .72 and AUC ¼ 0.91 for the full mHI-
UC). The UC DA-VAS was also correlated with the
endoscopic component of the Mayo score (r ¼ .55; P <
.0001), and had an AUC to predict endoscopic disease
activity of 0.79 (compared with r ¼ .60 and AUC ¼ 0.82
for the full mHI-UC). A significant difference between the
DA-VAS of patients with UC that deteriorated, remained
stable, or improved was observed (P ¼ .0052).Discussion
We developed 2 questionnaires of 4 items consisting
solely of PROs for remote monitoring of patients with
Figure 3. Sensitivity to
change (A and C) and test-
retest reliability (C and D)
of the mHI-CD (A and B)
and mHI-UC (C and D).
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questionnaires were validated in a multicenter validation
study and showed excellent characteristics to monitor
clinical disease activity and symptom changes. As previ-
ously shown, UC clinical disease activity highly correlates
with endoscopic disease activity, whereas correlation
between CD symptoms and endoscopic findings is poor.21
Although previous studies have aimed to identify
PROs for disease monitoring either by adjusting existing
questionnaires,16 or by using subcomponents of existing
questionnaires,18,19 we were able to prospectively iden-
tify PROs relevant for clinical disease monitoring and
validate those in an independent cohort. Interestingly,
patient-reported disease activity was shown to be an
independent predictor for clinical disease activity in
patients with UC and patients with CD, even after in-
clusion of common IBD symptoms, such as stool fre-
quency and abdominal pain. Patient-reported disease
activity alone had a comparable performance with the
complete mHI in both CD and UC for detecting clinical
and endoscopic activity, although responsiveness to
changes in disease activity was reduced in particular in
patients with CD.A limitation of this study is the potential for recall
bias in CDAI calculation. Although 7-day diary forms
were sent out in advance, we did not log whether diaries
were filled out daily or by recall. Additionally, in the
validation cohort, optimal cutoffs of the mHI for detec-
tion of disease activity were higher than expected for CD
and lower than expected for UC. This might be caused by
the reduction of questionnaire items from >20 PROs to
just 4, or by differences in the patient population. The
validation phase of the study most accurately represents
the real-life situation. Therefore, we implemented the
cutoff for optimal sensitivity and specificity as observed
in the validation cohort in clinical practice.
This study was not primarily designed to evaluate
correlations between PROs and endoscopic healing. In at-
risk patients, clinical assessments remain warranted,
which may lead to further endoscopic evaluation. This
tool offers an optimal screening method to monitor and
evaluate disease activity in and outside of clinical prac-
tice with a high NPV. The mHIs are currently imple-
mented in the UCLA eIBD patient app (Supplementary
Figure 2) and automated messages are sent to a nurse
coordinator when the mHI indicates disease activity. The
1750 Van Deen et al Clinical Gastroenterology and Hepatology Vol. 14, No. 12app is currently available to patients treated at the UCLA
Center for IBD and can be downloaded in iOS or Android
by searching for “UCLA eIBD.”
The calculation of the mHI is complex. However,
simplifying the score would most likely result in loss of
accuracy. Because the index is meant to be automated
and implemented on digital platforms, we believe that
using the more complex calculations is justified.
Cloud-based health technologies are predicted to
revolutionize care delivery and patient engagement. Pa-
tients can participate in their care by signaling meaningful
health outcomes during year-round monitoring. Barriers
for more widespread implementation of mHealth in IBD
care include policies affecting reimbursement and regula-
tory requirements,22 and privacy and security concerns.1
In summary, we developed the mHI-CD and mHI-UC
for remote monitoring of patients with CD and patients
with UC. The scores are specifically designed for imple-
mentation on a mobile application and are currently
available to patients with IBD treated at the UCLA Center
for IBD. Prospective randomized studies need to assess
the effect of remote monitoring on disease control,
quality of life, patient satisfaction, and health care costs.Supplementary Material
Note: To access the supplementary material accom-
panying this article, visit the online version of Clinical
Gastroenterology and Hepatology at www.cghjournal.org,
and at http://dx.doi.org/10.1016/j.cgh.2015.10.035.References
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Supplementary
Figure 1. Seven-day diary
form, which was sent to
patients to log symptoms
during the 7 days before
the clinic visit for calcula-
tion of the CDAI.
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Supplementary Figure 2. Screenshots of the mHI as implemented in the UCLA eIBD patient app available to patients treated
at the UCLA IBD Center.
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Supplementary Table 1. CD Variables, Univariate Logistic Regression Outcomes for Prediction of Active Disease (HBI>4)
Domain Variable n Cutoffs MLE SE Chi-square P value Modela Var#
Stool frequency Number of liquid/very soft stools
per day
108 Continuous 1.63 0.35 22.34 <.0001 —
0/1–3/>3 3.49 0.73 23.11 <.0001 —
0/1–2/>2 3.55 0.66 28.58 <.0001 1 V1.1
0/>0 3.36 0.77 19.10 <.0001 —
How many stools did you have
yesterday during the day?
108 Continuous 0.85 0.19 20.09 <.0001 —
0–1/>1 2.00 0.65 9.53 .0020 —
Number of stools more than
normal per day
108 Continuous 0.87 0.36 5.88 .015 —
0/>0 0.84 0.51 2.69 .10 —
Total number of stools per day 108 Continuous 0.97 0.20 22.75 <.0001 —
1/>1 1.75 0.77 5.08 .024 —
0–2/>2 2.58 0.55 22.19 <.0001 —
0–1/2–4/>4 2.64 0.58 20.79 <.0001 —
0–2/3–4/>4 2.16 0.40 28.49 <.0001 2 V1.2
Stools at night How many stools did you have
last night?
108 Continuous 0.88 0.26 11.59 .0007 —
0/>0 1.15 0.44 6.90 .0086 —
0/1/>1 0.99 0.30 11.01 .0009 —
0/1–2/>2 1.28 0.36 12.29 .0005 1, 2 V2
Abdominal pain Abdominal pain (no–severe) 108 No/mild/moderate/severe 2.68 0.50 28.11 <.0001 —
No/yes 3.72 0.62 35.35 <.0001 1, 2 V3
Abdominal pain (no pain–continuous) 108 No abdominal pain/with bowel actions/continuous 1.52 0.31 23.97 <.0001 —
Abdominal pain VAS 108 Continuous 0.51 0.10 24.99 <.0001 —
0–3/>3, <8/8–10 2.02 0.41 24.17 <.0001 —
<3/3–6/>6 1.94 0.39 25.03 <.0001 —
General well-being General well-being (very well– terrible) 108 Very well slightly below par/poor/very poor/terrible 1.31 0.30 18.93 <.0001 —
Well-being VAS 108 Continuous 0.47 0.11 18.44 <.0001 —
<4/4, <7/7 1.42 0.35 16.76 <.0001 —
2/>2, <7/7 1.80 0.40 20.09 <.0001 1, 2 V4
Well-being (no impairment–unable
to work)
108 No impairment/impaired but able to continue
activities/activities reduced/unable to work
1.21 0.83 17.90 <.0001 —
Urgency Urgency of defecation
(no urgency–incontinence)
108 No urgency/hurry/immediately/incontinence 1.30 0.32 16.99 <.0001 1, 2 V5
No incontinence/incontinence 0.88 1.43 0.38 .54 —
Stool consistency Stool consistency 108 Normal or variably normal/semiformed/liquid 2.09 0.48 19.06 <.0001 1, 2 V6
Do you take opiates or lomotil/imodium
for diarrhea?
108 No/yes 1.22 0.52 5.47 .019 —
Antidiarrheals VAS 108 Continuous 0.00 0.09 0.00 1.00 —
Rectal bleeding Rectal bleeding VAS 108 Continuous 0.16 0.09 3.06 .080 —
3/>3 1.22 0.52 5.47 .019 1, 2 V7
What % of bowel movements contains
visible blood?
108 None/<50%/50%/blood alone 0.36 0.34 1.08 .30 —
Amount of blood in stool 108 None/trace/occasionally frank/usually frank 0.61 0.28 4.72 .030 —
Fever Did you have fever yesterday? 108 No/yes 14.53 913.40 0.00 .99 —
Anorexia Loss of appetite 108 No/yes 1.04 0.45 5.51 .019 1, 2 V8















Supplementary Table 1. Continued
Domain Variable n Cutoffs MLE SE Chi-square P value Modela Var#
Disease activity Disease control VAS 108 Continuous 0.42 0.09 21.88 <.0001 —
3, >3, <7/7 1.60 0.32 24.41 <.0001 —
2, >2, <7/7 1.80 0.36 24.58 <.0001 1, 2 V10
Laboratory studies C-reactive protein (mg/dL) 93 Continuous 0.27 0.14 3.80 .051 —
0.8/>0.8 1.77 0.53 11.11 .0009 —
Calprotectin (mg/g) 63 Continuous 0.00 0.00 6.45 .011 —
<163/163 1.22 0.63 3.71 .054 —
<50/50 0.28 0.66 0.18 .67 —
White blood cell count (*103 cells/mL) 96 Continuous 0.15 0.08 3.20 .074 —
9.95/>9.95 1.06 0.66 2.60 .11 —
Albumin (g/dL) 94 Continuous -1.55 0.61 6.47 .011 —
3.7/<3.7 1.92 0.90 4.51 .034 —
Platelets (*103 cells/mL) 96 Continuous 0.00 0.00 1.43 .23 —
143/<143 15.17 770.20 0.00 .98 —
Erythrocyte sedimentation rate (mm/hr) 85 Continuous 0.05 0.02 7.28 .0070 —
22 (F) or 10 (M)/>22 (F) or >10 (M) 1.62 0.53 9.38 .0022 —
Hemoglobin (g/dL) 95 Continuous -0.10 0.14 0.59 .44 —
>11.6 (F) or >13.5 (M)/11.6 (F) or 13.5 (M) 1.15 0.50 5.24 .022 —
Hematocrit 96 Continuous -3.34 5.39 0.38 .54 —
>0.349 (F) or >0.385 (M)/0.349 (F) or 0.385 (M) 0.61 0.57 1.15 .28 —
F, female; M, male; MLE, maximum likelihood estimate, SE, standard error.





















Supplementary Table 2. UC Variables, Univariate Logistic Regression Outcomes for Prediction of Active Disease (pMayo >2)
Domain Variable n Cutoffs MLE SE Chi-square P value Modela Var#
Stool frequency How many stools did you have
yesterday during the day?
109 Continuous 0.87 0.79 20.57 <.0001 —
<3/3–4/5–6/7–9/>9 1.61 0.33 23.11 <.0001 —
<4/4–6/>6 2.24 0.50 19.69 <.0001 —
<4/4–6/>6 2.32 0.49 22.35 <.0001 —
Stools more than normal 109 Continuous 0.99 0.33 9.23 .0024 —
0/1–2/3–4/>4 1.65 0.41 16.17 <.0001 —
0/1–2/>2 1.78 0.41 19.18 <.0001 —
Total number of stools/day 109 Continuous 0.78 0.16 23.03 <.0001 —
<3/3–6/>6 2.24 0.42 28.86 <.0001 —
0–4/>4 3.57 0.62 32.79 <.0001 1, 2 V1.1
0–2/3–4/>4 1.95 0.34 32.46 <.0001 3, 4 V1.2
Stools at night How many stools did you
have last night?
109 Continuous 0.95 0.26 12.77 .0004 —
0/>0 1.48 0.43 11.79 .0006 —
0/1–3/>3 1.49 0.38 15.01 .0001 1, 2, 3, 4 V2
Abdominal pain Abdominal pain (no– severe) 109 No/mild/moderate/severe 0.78 0.25 9.60 .0019 —
No/yes 1.47 0.45 10.62 .0011 —
Abdominal pain (no– continuous) No abdominal pain 1.02 0.30 11.44 .0001 —
Abdominal pain VAS 109 Continuous 0.40 0.09 19.21 <.0001 —
<3/3, 6/>6 1.75 0.37 21.84 <.0001 1, 2, 3, 4 V3
0/>0, 4/>4 1.40 0.33 18.20 <.0001 —
General well-being General well-being? (very well–terrible) 109 Very well/slightly below par/poor/very poor/terrible 1.27 0.34 14.12 .0002 —
General well-being (perfect–terrible) 109 Perfect/very good/good/average/poor/terrible 0.91 0.23 16.08 <.0001 1, 3 V4.1
Well-being VAS 109 Continuous 0.43 0.11 15.30 <.0001 —
3/>3 1.62 0.45 13.31 .0003 —
3/>3, 6/>6 1.42 0.36 15.73 <.0001 2, 4 V4.2
Well-being (no impairment–unable
to work)
109 No impairment/impaired but able to continue
activities/activities reduced/unable to work
1.14 0.36 15.93 <.0001 —
Urgency Urgency of defecation 109 No urgency/hurry/immediate/incontinence 2.01 0.40 24.82 <.0001 —
No urgency/hurry/immediate 2.03 0.40 25.13 <.0001 1, 2, 3, 4 V5
No incontinence/incontinence 14.13 826.90 0.00 .99 —
Stool consistency Stool consistency 109 Normal or variably normal/semiformed/liquid 2.13 0.46 21.68 <.0001 1, 2, 3, 4 V6
Do you take opiates or
lomotil/imodium for diarrhea?
109 No/yes -0.03 0.59 0.00 .96 —
Antidiarrheals VAS 109 Continuous 0.05 0.09 0.26 .26 —
Rectal bleeding Rectal bleeding VAS 109 Continuous 0.59 0.11 27.82 <.0001 —
3/>3 2.71 0.49 29.97 <.0001 —
<2/2, <5/5, <8/8 1.66 0.31 28.15 <.0001 1, 2, 3, 4 V7
What % of bowel movements
contains visible blood?
109 None/<50%/50%/blood alone 2.84 0.59 22.89 <.0001 —
None/<50%/50% 2.95 0.60 24.26 <.0001 —
None/>0% 3.86 1.04 13.76 .0002 —
Amount of blood in stool 109 None/trace/occasionally frank/usually frank 1.83 0.35 27.22 <.0001 —
None/trace/more than a trace 1.95 0.37 27.53 <.0001 —
Anorexia Loss of appetite 109 No/yes 1.44 0.48 9.10 .0025 1, 2, 3, 4 V8















Supplementary Table 2. Continued
Domain Variable n Cutoffs MLE SE Chi-square P value Modela Var#
Disease activity Disease control VAS 109 Continuous 0.46 0.10 21.67 <.0001 —
3/>3, <7, 7 1.44 0.31 21.37 <.0001 —
2/>2, 5/>5 1.82 0.36 25.86 <.0001 1, 2, 3, 4 V10
2/>2, <7/7 1.68 0.36 21.76 <.0001 —
Labs C-reactive protein (mg/dL) 91 Continuous 1.03 0.42 5.87 .015 —
0.8/>0.8 1.50 0.55 7.35 .0067 —
Calprotectin (mg/g) 70 Continuous 0.00 0.00 4.31 .038 —
<163/163 1.29 0.56 5.22 .022 —
<50/50 1.96 0.80 6.06 .014 —
White blood cell count (*103 cells/mL) 93 Continuous 0.20 0.08 5.91 .015 —
9.95/>9.95 1.39 0.56 6.19 .013 —
Albumin (g/dL) 88 Continuous -1.52 0.66 5.39 .02 —
3.7/<3.7 14.36 610.50 0.00 .98 —
Platelets (*103 cells/mL) 93 Continuous 0.00 0.00 2.54 .11 —
143/<143 -12.66 805.50 0.00 .99 —
Erythrocyte sedimentation rate (mm/hr) 85 Continuous 0.04 0.01 8.38 .0038 —
22 (F) or 10 (M)/>22 (F) or >10 (M) 1.04 0.47 4.81 .028 —
Hemoglobin (g/dL) 93 Continuous -0.31 0.15 4.59 .032 —
>11.6 (F) or >13.5 (M)/11.6 (F) or 13.5 (M) 0.75 0.50 2.25 .13 —
Hematocrit 93 Continuous -9.46 5.91 2.66 .10 —
>0.349 (F) or >0.385 (M)/0.349 (F) or 0.385 (M) 1.84 0.65 7.99 .0047 —
F, female; M, male; MLE, maximum likelihood estimate, SE, standard error.





















Supplementary Table 3. Development and Evaluation of Composite Scores for CD
Composite score development AUC ROC curves P value
Dependent variable Model Variables in composite scoresa HBI CDAI HBI CDAI
HBI 1 V1.1; V3 0.981 0.912 0.903 0.739
2 V1.2; V3; V10 0.956 0.898 0.750 0.702
CDAI 1 V1.1; V3; V4; V10 0.951 0.963 0.837 0.830
2 V3; V4; V10 0.900 0.942 0.731 0.771
V1.1, number of liquid/very soft stools per day; V1.2, total number of stools per day; V3, abdominal pain; V4, well-being VAS; V10, disease control VAS.
aSee Supplementary Table 1 for full details on each variable.
Supplementary Table 4. Development and Evaluation of Composite Scores for UC
Composite score development AUC ROC curves P value
Dependent variable Model Variables in composite scoresa pMayo SCCAI MTWI pMayo SCCAI MTWI
pMayo 1, 2 V1.1; V3; V7; V8; V10 0.960 0.865 0.849 0.769 0.769 0.703
1, 2b V1.1; V3; V7; V10 0.957 0.879 0.883 0.797 0.803 0.762
3 V1.2; V3; V7; V8; V10 0.964 0.908 0.890 0.808 0.812 0.748
3b V1.2; V3; V7; V10 0.960 0.915 0.913 0.820 0.832 0.790
4 V1.2; V 4.2; V7; V10 0.956 0.920 0.909 0.809 0.838 0.787
SCCAI 1 V2; V4.1; V5; V7 0.872 0.974 0.896 0.711 0.907 0.836
2, 4 V2; V3; V4.2; V5; V7; V10 0.904 0.971 0.883 0.765 0.911 0.810
3 V1.2; V2; V4.1; V5; V7 0.885 0.981 0.923 0.721 0.914 0.869
MTWI 1 Unbalanced model NA NA NA NA NA NA
2 V1.1; V2; V6; V7; V8 0.928 0.879 0.937 0.801 0.806 0.855
3 V1.2; V2; V4.1 0.880 0.907 0.984 0.712 0.797 0.933
4 V1.2; V2; V4.2; V7; V8 0.906 0.894 0.950 0.777 0.810 0.866
MTWI, modified Truelove and Witts index; NA, not applicable; V1.1 and V1.2, number of stools per day; V2, number of stools at night; V3, abdominal pain VAS;
V4.1, general well-being; V4.2, well-being VAS; V5, urgency of defecation; V6, stool consistency; V7, rectal bleeding VAS; V8, anorexia; V10, disease control VAS.
aSee Supplementary Table 2 for full details on each variable.
bIn these models loss of appetite was excluded as independent variable because of a clinically irrelevant negative value in the model.
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